Curated News
By: NewsRamp Editorial Staff
June 02, 2026

Lantern Pharma’s LP-300 Shows Promising Progression-Free Survival in Lung Cancer

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • Lantern Pharma's LP-300 shows increasing survival benefit with longer treatment, offering a competitive edge in NSCLC therapy.
  • LP-300 combined with carboplatin and pemetrexed improved median progression-free survival to 8.9 months in L858R-mutant NSCLC patients.
  • Lantern Pharma's AI-driven platform advances precision oncology, potentially improving outcomes for lung cancer patients with limited options.
  • Lantern Pharma's FDA-cleared protocol now allows LP-300 dosing up to eight cycles, extending treatment duration for better results.

Impact - Why it Matters

This news matters because it highlights a potential new treatment option for patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer who have exhausted TKI therapy. The improved progression-free survival and clean safety profile could address a significant unmet need in this specific patient population. Additionally, Lantern’s AI-driven approach, including the commercially available withZeta.ai platform, signals a shift toward more efficient and targeted drug development, which could accelerate the delivery of effective therapies to patients.

Summary

Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, has reported updated Phase 2 HARMONIC trial data showing that its drug LP-300, in combination with carboplatin and pemetrexed, demonstrated a progression-free survival benefit that increased with treatment duration in patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer who had progressed following TKI therapy. The emerging data showed a median progression-free survival of 8.9 months among L858R patients treated through up to six cycles, compared with 8.4 months across the overall L858R cohort, while maintaining what the company described as an exceptionally clean safety and tolerability profile. This supports a recently FDA-cleared protocol amendment extending LP-300 dosing from six to eight cycles. LP-300 is a cisplatin/ethacraplatin analog being evaluated in never-smoker patients with relapsed advanced lung adenocarcinoma.

Lantern Pharma leverages AI, machine learning, and its proprietary RADR(R) platform to transform cancer therapy development. Its clinical pipeline includes LP-184 (acylfulvene) and LP-284 (a TC-NER targeting compound). LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. Additionally, withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical community, representing a new revenue stream. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.

Investors can follow the latest news and updates relating to LTRN in the company’s newsroom at https://ibn.fm/LTRN. BioMedWire, a specialized communications platform focusing on biotechnology and life sciences, is one of the brands within the Dynamic Brand Portfolio @ IBN that delivers press release distribution and corporate communications solutions.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma’s LP-300 Shows Promising Progression-Free Survival in Lung Cancer

blockchain registration record for this content.